Baxter International Q3 2026: sales up 5% to $2.98B, but adjusted EPS fell 16% to $0.58 on a higher tax rate

Baxter International's third quarter of 2026 (three months to September 30) was the second quarter in a row with 5% sales growth, to $2.98 billion, and this time every segment and division grew. The profit line tells two different stories. On a GAAP basis (the official accounting rules), Baxter swung from a $46 million loss to $294 million of net income, or $0.57 per diluted share. But $0.38 of that came from a one-time gain on retiring debt cheaply. On Baxter's own adjusted basis, which strips out one-offs and acquisition amortization, EPS fell 16% to $0.58, and almost all of the drop is a higher tax rate: adjusted profit before tax was flat at $371 million against $372 million. These figures come from the earnings release; the full 10-Q is not filed yet, so the management discussion behind some line items is not available.

NM = not meaningful (a swing from loss to profit has no sensible percentage). The Q3 2025 GAAP EPS of −$0.09 is total; continuing operations alone were −$0.10. GAAP results are continuing operations except net income and total EPS, which include a $4M loss from the discontinued Kidney Care business.

Where the growth came from

Baxter now reports two segments. Medical Products & Therapies (IV solutions, infusion pumps, drug compounding, injectable drugs, surgical products) is about 70% of sales. Healthcare Systems & Technologies (hospital beds, patient monitors, surgical tables and operating-room equipment, the former Hillrom business) is most of the rest.

• Advanced Surgery (hemostats and sealants that control bleeding in surgery) is the fastest grower again at +12%, in both the U.S. (+11%) and abroad (+13%). The release credits "continued strong global demand."
• Infusion Therapies & Platforms, the largest division, grew 4% organically on infusion systems, drug compounding and IV solutions, "partially offset by reduced sales within Injectables." The adjustments table also shows restructuring costs tied to "the cessation of production of certain products at one of its specialty injectables manufacturing facilities", so injectables is shrinking partly by choice.
• Healthcare Systems & Technologies grew 4%, with Front Line Care (monitors and diagnostic devices, which took a goodwill write-down in late 2025) up 3% after 2% in Q2. Its segment margin (segment profit as a share of segment sales) rose 1.4 points to 17.2%.
• Sales to Vantive under the supply agreement fell 20% to $68M. Baxter leaves these out of organic growth, which is why U.S. sales rose 3% reported but 5% organically.

Segment operating profit rose 9% to $588M, faster than sales. But unallocated corporate costs (head-office spending not charged to a segment) rose to $156M from $115M, which ate most of that gain. That is why adjusted operating income rose only 2%, to $432M.

What the headline numbers hide

• The GAAP turnaround is mostly one-offs, in both years. This quarter includes a $253M pre-tax ($195M after tax, $0.38 per share) "gain on debt extinguishment": Baxter paid $600M in a tender offer for long-dated bonds with a face value of $864M. Bonds issued when interest rates were low trade below face value now, so buying them back early books a gain. It is real money saved on future repayment, but it will not recur. There was also a $27M net legal gain, mostly from settling patent claims. On the other side, the year-ago quarter carried a $213M tax charge (uncertain tax positions and Swiss valuation allowances) and $32M of infusion-pump warranty and remediation costs. Neither recurred. Remove all of these, plus $145M of acquisition amortization and $61M of restructuring, and both years land on adjusted figures: $0.58 versus $0.69.
• The GAAP-to-adjusted gap is small this quarter, but only because items cancel out. GAAP EPS of $0.57 and adjusted EPS of $0.58 look nearly identical. Underneath, $0.21 of amortization, $0.09 of restructuring, $0.08 of tax items and $0.03 of "business transformation" (systems and process modernization) costs are added back, and the $0.38 bond gain and $0.04 legal gain are taken out. Restructuring rose to $61M from $38M, and business transformation costs ($54M so far this year) are a new exclusion in 2026. Both are recurring enough to watch.
• The adjusted decline is a tax story. Adjusted pre-tax profit was $371M against $372M. Adjusted tax expense rose to $68M from $19M as the rate went from 5.1% to 18.3%. Last year's 5.1% was unusually low, so part of this is a harsh comparison rather than a weaker business. The release gives no explanation for the rate.
• Margins: still below last year, but the gap is narrowing. Adjusted gross margin (sales minus the cost of making the products, before special items) was 38.3% against 39.4%, down 1.1 points. In Q2 it was down 2.1 points. Lower adjusted SG&A, at 21.4% of sales against 22.2%, offset most of that.
• Cash conversion was strong. Operating cash flow from continuing operations was $558M against $299M of adjusted net income. Free cash flow was $448M for the quarter and $705M for nine months, compared with −$18M in the first nine months of 2025.
• No buyback help. Diluted shares rose 1.2%, to 520M from 514M, so EPS was not lifted by a smaller share count. The quarterly dividend is $0.01 a share (re-declared on October 28). The release does not give cash paid for dividends or repurchases; the 10-Q will.

On balance, the quarter is flattered on a GAAP basis. The swing from a $0.10 loss to $0.57 of EPS rests on a $0.38 bond-retirement gain and a large prior-year tax charge that did not recur, while adjusted EPS, the figure management guides to, fell 16%.

Did last time's read hold up?

Our Q2 2026 report named three things to watch:

1. Whether gross margin recovers in the second half. Partly. The adjusted gross-margin decline narrowed from 2.1 points to 1.1, and Medical Products & Therapies' segment margin was flat at 20.9% after falling by about 3.5 points in Q2. The margin is still below last year.
2. Whether the Novum IQ infusion pump returns to market. The release gives no update on a U.S. relaunch. Its risk-factor list now refers to quality issues "with respect to the Novum IQ large volume pump and a recently issued U.S. Food and Drug Administration Warning Letter". A Warning Letter is the FDA's formal notice that it found significant compliance problems. That points away from a quick return.
3. Whether the leverage waiver is a bridge or lasting strain. The tender closed and retired $864M of debt for $600M of cash, and quarterly free cash flow of $448M was the strongest this year. That looks more like a bridge.

Takeaway: Baxter's sales recovery is broad: 5% organic growth, every division up, and a guidance raise. But the profit picture is weaker than GAAP shows. Adjusted pre-tax profit was flat, adjusted EPS fell 16% on a higher tax rate, and the GAAP swing to a $0.57 profit leans on a $0.38 one-time gain from buying back bonds below face value.

Guidance and outlook

Management raised its full-year 2026 outlook again, after a raise in July:

Baxter expects currency to add about one percentage point to reported growth. The EPS raise lifts only the bottom of the range, so the midpoint moves from $2.05 to $2.10. Adjusted EPS from continuing operations was $1.51 for the first nine months, which implies $0.54–$0.64 for Q4. With Q3 at $0.58, the guide assumes roughly a repeat of this quarter rather than the second-half step-up the July guidance implied.

Our read: the top line has turned. Organic growth was 5% in both Q2 and Q3 (3% for the nine months), and the balance sheet is improving faster than expected through free cash flow and the discounted bond buyback. What has not yet turned is profitability: gross margin is still below last year, corporate costs are rising, and a normal tax rate takes away what operations add. Things to watch in Q4 and the 10-Q: whether adjusted gross margin gets back to last year's level, what the FDA Warning Letter covers and whether it delays the Novum IQ pump further, and whether the 18.3% adjusted tax rate is the new normal.

Source: Baxter International Q3 2026 earnings release (Exhibit 99.1 to Form 8-K filed October 29, 2026). Segment margins and adjusted pre-tax figures are as reported in the release's reconciliation tables. The Form 10-Q for the quarter has not been filed yet.